+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-07-25Number of Pages: 202

Bioengineered Protein Drugs Market (Drug Type - Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis), Therapeutic Proteins (Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytics), and Vaccines; Disease Condition - Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, and Neurodegenerative; End User - Pharmaceutical and Biotechnology Companies, CROs, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Bioengineered Protein Drugs Market: Snapshot

Majorly fuelling the global bioengineered protein drugs market is the rising occurrence of infectious diseases, diabetes, cancer, etc. This is because bioengineered protein drugs are more effective and additionally have reduced or no side effects when compared with alternative therapies for cancer, diabetes, and other maladies. This has led to more healthcare physicians prescribing these drugs, thereby stoking demand in the market.

The prospects in the global market for bioengineered protein drugs also looks upbeat owing to increasing drugs in phase III of clinical trials and many companies pouring money into research and development of novel bioengineered proteins.

Posing a roadblock to the market, on the other hand, is the steep cost of manufacturing bioengineered protein drug, having shorter shelf life. The emergence of biosimilars is also posing a severe challenge to the growth in the market.

A report by Transparency Market Research predicts the global bioengineered protein drugs market to expand at a 7.4% CAGR from 2017 to 2024 to become worth US$336.9 bn by 2025 from US$177.7 bn in 2016.

global bioengineered protein drugs market

Vaccines Slated to Grow at Maximum Pace due to Development of Bioengineered Prophylactic Vaccines

The global bioengineered protein drugs market can be classified into monoclonal antibodies, vaccines, and therapeutic protein based upon the type of product. The therapeutic protein segment, among them, accounts for a dominant share because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products. In terms of growth rate, however, the vaccines segment is expected to outshine all other segments by clocking maximum CAGR between 2017 to 2025 because of increase in development of bioengineered prophylactic and therapeutics vaccines.

Rising Instances of Cancer Propels North America Market to Fore

From a geographical standpoint, North America leads the global bioengineered protein drugs market. In the years ahead, the region is slated is maintain its dominant position because of the rising occurrence of cancer and unveiling of innovative protein therapeutics for cancer. While loss of patents of blockbuster drugs such as Humira, Rituxan, Avastin, and Remicade, among others, are expected to deal a blow to the revenue in the market, launch of new drugs and approvals for new diagnostic tests, along with a growing geriatric population and unhealthy lifestyle will likely make up for it by inducing growth. As per the TMR report, the bioengineered protein drugs market in North America will likely register a CAGR of 7.2% from 2017 to 2025 to become worth US$161.05 bn by 2025.

Though trailing North America, in terms of size, Europe is expected to lag behind all other regions vis-à-vis growth rate because of the patent loss of blockbuster drugs such as Humira, Avastin, and Lucentis and emergence of biosimilars.

Powered by India, China, and South Korea, Asia Pacific is expected to steal the show in the near future by expanding at a maximum CAGR of 9.0% from 2017 to 2025. Growing occurrence of cancer, massive investments by players, and rapid rise in healthcare infrastructure are said to be boosting growth in the region. China is at the forefront of driving growth in the region because of the sizeable proportion cancer patients, increasing geriatric population, launch of premium-priced targeted therapies, and rise in number of people covered under private health insurance in the country.

Some of the key players in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Johnson & Johnson (JanssenNovartis AG, Panacea Biotec, and ProBioGen AG.

1 Preface
    1.1 Market Definition and Scope
    1.2 Market Segmentation
    1.3 Key Research Objectives
    1.4 Research Highlights

2 Assumptions and Research Methodology

3 Executive Summary: Global Bioengineered Protein Drugs  Market

4 Market Overview
    4.1 Introduction
          4.1.1 Product Overview
          4.1.2 Industry Evolution / Developments
          4.1.3 Key Market Indicators
    4.2 Market Dynamics 
          4.2.1 Drivers
          4.2.2 Restraints
          4.2.3 Opportunity
    4.3 Market Revenue Projections
    4.4 Porter’s Five Force Analysis
    4.5 Value Chain Analysis
    4.6 Market Outlook

5 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Drug Type
    5.1 Key Findings / Developments
    5.2 Introduction & Definition    
    5.3 Market Value Forecast by Drug Type, 2017–2025
          5.3.1 Monoclonal Antibody
                   5.3.1.1 Humira
                   5.3.1.2 Rituxan
                   5.3.1.3 Avastin
                   5.3.1.4 Herceptin
                   5.3.1.5 Remicade
                   5.3.1.6 Lucentis
                   5.3.1.7 Enbrel 
                   5.3.1.8 Synazis
                   5.3.1.9 others
          5.3.2 Therapeutic Proteins Market By Type 
                   5.3.2.1 Hormones
                   5.3.2.2 Cytokines
                             5.3.2.2.1 Neupogen
                             5.3.2.2.2 Neulasta
                             5.3.2.2.3 Interferon Alpha
                             5.3.2.2.4 Erythropoietin Alpha
                             5.3.2.2.5 Interleukin
                             5.3.2.2.6 Others
                   5.3.2.3 Blood Factor
                   5.3.2.4 Enzyme Therapy
                             5.3.2.4.1 Systemic Enzyme Therapy
                             5.3.2.4.2 Digestive Enzyme Therapy
                   5.3.2.5 Thrombolytics
                             5.3.2.5.1 tPA
                             5.3.2.5.2 Streptokinase
                             5.3.2.5.3 Urokinase
                   5.3.2.6 Vaccines
    5.4 Key Trends
    5.5 Market Attractiveness by Drug Type

6 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Disease Condition
    6.1 Key Findings / Developments
    6.2 Introduction & Definition
    6.3 Market Value Forecast by Disease Condition, 2017–2025
          6.3.1 Cancer
          6.3.2 Diabetes
          6.3.3 Autoimmune Disorder
          6.3.4 Infectious Disease
          6.3.5 Hematopoiesis
          6.3.6 CVD
          6.3.7 Neurodegenerative
          6.3.8 Others
    6.4 key Trends
    6.5 Market Attractiveness by Disease Condition

7 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by End-user
    7.1 Key Findings / Developments    
    7.2 Introduction & Definition
    7.3 Market Value Forecast by End-user, 2017–2025
          7.3.1 Pharma and Biotech Companies
          7.3.2 CROs
          7.3.3 Research Institutes
    7.4 Key Trends
    7.5 Market Attractiveness by End-user

8 Global Bioengineered Protein Drugs  Market Analysis and Forecasts, by Region
    8.1 Policies and Regulations
    8.2 Market Value Forecast by Region
          8.2.1 North America 
          8.2.2 Europe 
          8.2.3 Asia Pacific 
          8.2.4 Latin America  
          8.2.5 Middle East & Africa 
    8.3 Market Attractiveness by Region

9 North America Bioengineered Protein Drugs  Market Analysis and Forecasts
    9.1 Market Value Forecast by Country, 2017–2025
          9.1.1 U.S.
          9.1.2 Canada
    9.2 Market Value Forecast by Drug Type, 2017–2025
    9.3 Market Value Forecast by Disease Condition, 2017–2025
    9.4 Market Value Forecast by End - User, 2017–2025
    9.5 Market Attractiveness Analysis 
          9.5.1 By Country
          9.5.2 By Drug Type 
          9.5.3 By Disease Condition 
          9.5.4 By End-user

10 Europe Bioengineered Protein Drugs  Market Analysis and Forecasts
    10.1 Market Value Forecast by Country, 2017–2025
          10.1.1 Germany
          10.1.2 Italy 
          10.1.3 France 
          10.1.4 U.K.
          10.1.5 Spain
          10.1.6 Rest of Europe 
    10.2 Market Value Forecast by Drug Type, 2017–2025
    10.3 Market Value Forecast by Disease Condition, 2017–2025
    10.4 Market Value Forecast by End-user, 2017–2025
    10.5 Market Attractiveness Analysis 
          10.5.1 By Country
          10.5.2 By Drug Type 
          10.5.3 By Disease Condition 
          10.5.4 By End-user

11 Asia Pacific Bioengineered Protein Drugs  Market Analysis and Forecasts
    11.1 Market Value Forecast by Country, 2017–2025
          11.1.1 Japan
          11.1.2 China 
          11.1.3 India
          11.1.4 Rest of APAC
    11.2 Market Value Forecast by Drug Type, 2017–2025
    11.3 Market Value Forecast by Disease Condition, 2017–2025
    11.4 Market Value Forecast by End-user, 2017–2025
    11.5 Market Attractiveness Analysis 
          11.5.1 By Country
          11.5.2 By Drug Type 
          11.5.3 By Disease Condition
          11.5.4 By End-user

12 Latin America Bioengineered Protein Drugs  Market Analysis and Forecasts
    12.1 Market Value Forecast by Country, 2017–2025
          12.1.1 Brazil
          12.1.2 Mexico
          12.1.3 Rest of LATAM     
    12.2 Market Value Forecast by Drug Type, 2017–2025
    12.3 Market Value Forecast by Disease Condition, 2017–2025
    12.4 Market Value Forecast by End-user, 2017–2025
    12.5 Market Attractiveness Analysis 
          12.5.1 By Country
          12.5.2 By Drug Type 
          12.5.3 By Disease Condition 
          12.5.4 By End-user

13 Middle East & Africa Bioengineered Protein Drugs  Market Analysis and Forecasts
    13.1 Market Value Forecast by Country, 2017–2025
          13.1.1 South Africa
          13.1.2 Saudi Arabia
          13.1.3 Rest of MEA 
    13.2 Market Value Forecast by Drug Type, 2017–2025
    13.3 Market Value Forecast by Disease Condition, 2017–2025
    13.4 Market Value Forecast by End-user, 2017–2025
    13.5 Market Attractiveness Analysis 
          13.5.1 By Country
          13.5.2 By Drug Type 
          13.5.3 By Disease Condition
          13.5.4 By End-user

14 Competitive Landscape
    14.1 Market Share Analysis by Company 2016
    14.2 Company Profiles 
          14.2.1 Abbott Laboratories
                   14.2.1.1 Company Details
                   14.2.1.2 Company Description
                   14.2.1.3 Business Overview
                   14.2.1.4 SWOT Analysis
                   14.2.1.5 Financial Analysis
                   14.2.1.6 Strategic Overview
          14.2.2 Amgen Inc. 
                   14.2.2.1 Company Details
                   14.2.2.2 Company Description
                   14.2.2.3 Business Overview
                   14.2.2.4 SWOT Analysis
                   14.2.2.5 Financial Analysis
                   14.2.2.6 Strategic Overview
          14.2.3 Bayer AG
                   14.2.3.1 Company Details
                   14.2.3.2 Company Description
                   14.2.3.3 Business Overview
                   14.2.3.4 SWOT Analysis
                   14.2.3.5 Financial Analysis
                   14.2.3.6 Strategic Overview
          14.2.4 Biocon Ltd.
                   14.2.4.1 Company Details
                   14.2.4.2 Company Description
                   14.2.4.3 Business Overview
                   14.2.4.4 SWOT Analysis
                   14.2.4.5 Financial Analysis
                   14.2.4.6 Strategic Overview
          14.2.5 Dr. Reddy’s Laboratories       
                   14.2.5.1 Company Details
                   14.2.5.2 Company Description
                   14.2.5.3 Business Overview
                   14.2.5.4 SWOT Analysis
                   14.2.5.5 Financial Analysis
                   14.2.5.6 Strategic Overview
          14.2.6 Eli Lilly and Comapny 
                   14.2.6.1 Company Details
                   14.2.6.2 Company Description
                   14.2.6.3 Business Overview
                   14.2.6.4 SWOT Analysis
                   14.2.6.5 Financial Analysis
                   14.2.6.6 Strategic Overview
          14.2.7 F. Hoffmann – La Roche Ltd.
                   14.2.7.1 Company Details
                   14.2.7.2 Company Description
                   14.2.7.3 Business Overview
                   14.2.7.4 SWOT Analysis
                   14.2.7.5 Financial Analysis
                   14.2.7.6 Strategic Overview
          14.2.8 Fresenius kabi
                   14.2.8.1 Company Details
                   14.2.8.2 Company Description
                   14.2.8.3 Business Overview
                   14.2.8.4 SWOT Analysis
                   14.2.8.5 Financial Analysis
                   14.2.8.6 Strategic Overview
          14.2.9 GlaxoSmithKline plc
                   14.2.9.1 Company Details
                   14.2.9.2 Company Description
                   14.2.9.3 Business Overview
                   14.2.9.4 SWOT Analysis
                   14.2.9.5 Financial Analysis
                   14.2.9.6 Strategic Overview
          14.2.10 Johnson & Johnson (Janseen)
                   14.2.10.1 Company Details
                   14.2.10.2 Company Description
                   14.2.10.3 Business Overview
                   14.2.10.4 SWOT Analysis
                   14.2.10.5 Financial Analysis
                   14.2.10.6 Strategic Overview
          14.2.11 Merck & Co., Inc.
                   14.2.11.1 Company Details
                   14.2.11.2 Company Description
                   14.2.11.3 Business Overview
                   14.2.11.4 SWOT Analysis
                   14.2.11.5 Financial Analysis
                   14.2.11.6 Strategic Overview
          14.2.12 Novartis AG
                   14.2.12.1 Company Details
                   14.2.12.2 Company Description
                   14.2.12.3 Business Overview
                   14.2.12.4 SWOT Analysis
                   14.2.12.5 Financial Analysis
                   14.2.12.6 Strategic Overview
          14.2.13 Panacea Biotec
                   14.2.13.1 Company Details
                   14.2.13.2 Company Description
                   14.2.13.3 Business Overview
                   14.2.13.4 SWOT Analysis
                   14.2.13.5 Financial Analysis
                   14.2.13.6 Strategic Overview
          14.2.14 ProBioGen AG
                   14.2.14.1 Company Details
                   14.2.14.2 Company Description
                   14.2.14.3 Business Overview
                   14.2.14.4 SWOT Analysis
                   14.2.14.5 Financial Analysis
                   14.2.14.6 Strategic Overview
          14.2.15 Reliance Life Science Pvt. Ltd.
                   14.2.15.1 Company Details
                   14.2.15.2 Company Description
                   14.2.15.3 Business Overview
                   14.2.15.4 SWOT Analysis
                   14.2.15.5 Financial Analysis
                   14.2.15.6 Strategic Overview
          14.2.16 Sanofi
                   14.2.16.1 Company Details
                   14.2.16.2 Company Description
                   14.2.16.3 Business Overview
                   14.2.16.4 SWOT Analysis
                   14.2.16.5 Financial Analysis
                   14.2.16.6 Strategic Overview

List of Figures

Figure 1: Global Bioengineered Protein Drugs Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Market Value Share, by Drug Type (2016)
Figure 3: Market Value Share, by Disease Condition (2016)
Figure 4: Market Value Share, by End-User (2016)
Figure 5: Market Value Share, by Region (2016)
Figure 6: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 7: Global Monoclonal Antibodies Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 8: Global Therapeutic Proteins Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 9: Global Cytokines Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 10: Global Thrombolytics Drugs Market Value Share Analysis, by Type, 2016 and 2025
Figure 11: Global Enzyme Therapy Market Value Share Analysis, by Type, 2016 and 2025
Figure 12: Global Therapeutic Proteins Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 13: Global Monoclonal Antibodies Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 14: Global Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 15: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Drug Type
Figure 16: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Disease Condition, 2016 and 2025
Figure 17: Global Cancer Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 18: Global Diabetes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 19: Global Infectious Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 20: Global Autoimmune Disorders Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 21: Global Hematopoiesis Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 22: Global CVD Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 23: Global Neurodegenerative Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 24: Global Others Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 25: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Disease Condition
Figure 26: Global Bioengineered Proteins Drugs Market Value Share Analysis, by End-users, 2016 and 2025
Figure 27: Global Pharmaceutical Companies and Biotechnological Companies Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 28: Global Contract Research Organizations Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017-2025
Figure 29: Global Research Institutes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2025
Figure 30: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by End-users
Figure 31: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 32: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 33: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 34: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 35: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 36: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region
Figure 37: U.S. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 38: Canada Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 39: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 40: North Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 41: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 42: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 43: Germany Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 44: France Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 45: U.K. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 46: Italy Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 47: Spain Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 48: Rest of Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 49: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 50: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 51: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 52: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 53: China Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 54: Japan Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 56: Australia Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 57: Rest of APAC Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 58: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 59: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 60: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 61: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 62: Brazil Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 63: Mexico Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 64: Rest of LATAM Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 65: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 66: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 67: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 68: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 69: GCC Countries Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 70: South Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 71: Rest of MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 72: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 73: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 74: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 75: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 76: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 77: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 78: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition
Figure 79: India Bioengineered Protein Drugs Market Attractiveness Analysis, by End-users
Figure 80: Monoclonal Antibodies Bioengineered Protein Therapeutics Market Share Analysis By Company (2016)

List of Tables

Table 1: Table 1: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 2: Global Monoclonal Antibodies Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 3: Global Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 4: Global Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 5: Global Thrombolytics Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 6: Global Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 7: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 8: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by End-users, 2017–2025
Table 9: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2025
Table 10: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 11: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 12: North America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 13: North America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 14: North America Cytokine Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 15: North America Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 16: North America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 17: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 18: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 19: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 20: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 21: Europe Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 22: Europe Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 23: Europe Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 24: Europe Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 25: Europe Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 26: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 27: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 28: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 29: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 30: Asia Pacific Monoclonal Antibody Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 31: Asia Pacific Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 32: Asia Pacific Cytokines Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 33: Asia Pacific Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 34: Asia Pacific Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 35: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 36: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 37: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 38: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 39: Latin America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 40: Latin America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 41: Latin America Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 42: Latin America Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 43: Latin America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 44: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 45: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 46: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
Table 47: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 48: MEA Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 49: MEA Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 50: MEA Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 51: MEA Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 52: MEA Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 53: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 54: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025
Table 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2017–2025
Table 56: India Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 57: India Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 58: India Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 59: India Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2017–2025
Table 60: India Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2017–2025
Table 61: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2017–2025
Table 62: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2017–2025

Global Bioengineered Protein Drugs Market: Overview

This report provides in-depth region wise and country wise analysis of the bioengineered protein drugs market. Stakeholders of this report include manufacturers of bioengineered protein drugs, raw material suppliers, research institutes involve in the research of bioengineered protein drugs and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the global bioengineered protein drugs market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes major players with their reported revenue, market size, and forecast for the global bioengineered protein drugs market in major countries globally such as the U.S., Canada, Germany, Italy, France, United Kingdom, Spain, Japan, China, Brazil, Mexico, South Africa and GCC countries. Market revenue is provided in terms of US$ Mn from 2015 to 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 for all the segments, considering 2016 as the base year. The executive summary of the report provides a snapshot of the bioengineered protein drugs  with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global bioengineered protein drugs market. These factors would aid the stakeholders in establishing a strong foothold in the global bioengineered protein drugs market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the bioengineered protein drugs market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market.

Global Bioengineered Protein Drugs Market: Segmentation

The bioengineered protein drugs market has been segmented as by drug type, by disease condition, by end-user and by geography. Based on drug type, the market has been segmented into monoclonal antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, and Others) therapeutic proteins (hormones, cytokines, blood factor, enzyme therapy, thrombolytics, and others) vaccines. Based on disease condition, the market has been segmented into cancer, diabetes, autoimmune disorder, infectious disease, hematopoiesis, CVD, neurodegenerative, and others. Based on end-user, the market has been segmented into pharmaceutical & biotechnology companies, CROs, research institutes.

Global Bioengineered Protein Drugs Market: Geographical Analysis

Geographically, the bioengineered protein drugs market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, Italy, France, U.K., Spain, Rest of Europe, Japan, China, India, Rest of APAC, Brazil, Mexico, Rest of LATAM, South Africa, GCC countries have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the bioengineered protein drugs market in various regions has been provided in this section.

This report also includes various ups and downs about particular country or geography that has impacted the overall market globally.

Global Bioengineered Protein Drugs Market: Competitive Analysis

The report provides a detailed outline/blueprint of the bioengineered protein drugs market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market. The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Merck & Co., Inc., Reliance Life Sciences Pvt. Ltd., Panacea Biotech, ProBioGen AG, GlaxoSmithKline plc., and F. Hoffmann-La Roche Ltd

The global Bioengineered Protein Drugs market has been segmented into:

  • Global Bioengineered Protein Drugs Market, by Drug Type
    • Monoclonal Antibodies
      • Humira
      • Rituxan
      • Avastin
      • Herceptin
      • Remicade
      • Lucentis
      • Enbrel
      • Synazis
      • Others
    • Therapeutic Proteins
      • Hormones
      • Cytokines
        • Neupogen
        • Neulasta
        • Interferon Alpha
        • Erythropoietin Alpha
        • Interleukin
        • Others
      • Blood Factor
      • Enzyme Therapy
        • Systemic Enzyme Therapy
        • Digestive Enzyme Therapy
      • Thrombolytics
        • tPA
        • Streptokinase
        • Urokinase
    • Vaccines
       
  • Global Bioengineered Protein Drugs Market, by Disease Condition
    • Cancer
    • Diabetes
    • Autoimmune Disorder
    • Infectious Disease
    • Hematopoiesis
    • CVD
    • Neurodegenerative
    • Others
       
  • Global Bioengineered Protein Drugs Market, by End-user
    • Pharma and Biotech Companies
    • CROs
    • Academics
       
  • Global Bioengineered Protein Drugs Market, by Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific (APAC)
      • Japan
      • China
      • India
      • Australia
      • Rest of APAC
    • Latin America (LATAM)
      • Brazil
      • Mexico
      • Rest of LATAM
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA


 
 
Back To Top